United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Zacks Investment Research • Aug 6, 2026

United Therapeutics Q2 Earnings Call Highlights

United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the year but did not reaffirm or update previous 2026 revenue-growth expectations.

MarketBeat • Aug 5, 2026

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025. “We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinepag t.

Business Wire • Aug 5, 2026

United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82 per share. This compares to earnings of $6.41 per share a year ago.

Zacks Investment Research • Aug 5, 2026

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 5, 2026

UTHR or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Aug 3, 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.

Business Wire • Jul 29, 2026

United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?

9,500 shares were disposed of for ~$5.0 million based on a weighted average execution price of $530.42 on July 27, 2026. The transaction represents a 1% reduction in total equity holdings, leaving the insider with ~669,000 shares across direct and indirect accounts.

The Motley Fool • Jul 28, 2026

Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.

Zacks Investment Research • Jul 24, 2026